Literature DB >> 3886495

Role of whole abdominal radiation therapy in the management of endometrial cancer; prognostic importance of factors indicating peritoneal metastases.

R A Potish, L B Twiggs, L L Adcock, K A Prem.   

Abstract

From 1973 through 1983, 27 women received postoperative open-field external beam abdominal radiotherapy as primary treatment of endometrial carcinoma. The 5-year survival rate was 71%. Two distinct prognostic groups were demonstrated. Patients with spread to the adnexa, peritoneal fluid, or both, had a 5-year relapse-free rate of 90%. Patients with macroscopic spread of cancer beyond the adnexa had a 5-year relapse-free rate of 0%. Guidelines are suggested for the radiotherapeutic management of endometrial cancer metastatic to the peritoneal cavity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886495     DOI: 10.1016/0090-8258(85)90235-5

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Pathophysiology and management of endometrial hyperplasia and carcinoma.

Authors:  Y S Fu; J C Gambone; J S Berek
Journal:  West J Med       Date:  1990-07

2.  Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study.

Authors:  Ryan J Delahanty; Alicia Beeghly-Fadiel; Yong-Bing Xiang; Jirong Long; Qiuyin Cai; Wanqing Wen; Wang-Hong Xu; Hui Cai; Jing He; Yu-Tang Gao; Wei Zheng; Xiao Ou Shu
Journal:  Am J Epidemiol       Date:  2011-10-05       Impact factor: 4.897

Review 3.  Treatment for advanced and recurrent endometrial carcinoma: combined modalities.

Authors:  J Alejandro Rauh-Hain; Marcela G Del Carmen
Journal:  Oncologist       Date:  2010-07-21

4.  The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.

Authors:  Nick M Spirtos; Danielle Enserro; Howard D Homesley; Susan K Gibbons; David Cella; Robert T Morris; Koen DeGeest; Roger B Lee; David S Miller
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

5.  The effect of cell type on surgico-pathologic risk factors in endometrial cancer.

Authors:  Ahmet Taner Turan; Betül Dündar; Burcu Gündoğdu; Abdullah Boztosun; Nejat Ozgül; Nurettin Boran; Gökhan Tulunay; Ahmet Ozfuttu; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

6.  Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it.

Authors:  Jeanine N Staples; Lisa Rauh; M Sean Peach; William D Baker; Susan C Modesitt
Journal:  Gynecol Oncol Rep       Date:  2018-04-24

7.  Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

Authors:  David S Miller; Virginia L Filiaci; Robert S Mannel; David E Cohn; Takashi Matsumoto; Krishnansu S Tewari; Paul DiSilvestro; Michael L Pearl; Peter A Argenta; Matthew A Powell; Susan L Zweizig; David P Warshal; Parviz Hanjani; Michael E Carney; Helen Huang; David Cella; Richard Zaino; Gini F Fleming
Journal:  J Clin Oncol       Date:  2020-09-29       Impact factor: 44.544

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.